

## State of Oklahoma SoonerCare

## Besponsa® (inotuzumab ozogamicin) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	n
Physician billing (HCPCS code:) Start Date (or date of next dose):		
Dose:	ose:Regimen:	
	Billing Provider Inform	mation
Provider NPI:	Provider Name:	
Provider Phone:	Provider Fax:	
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria		
<ol> <li>Please indicate the diagnormal.</li> <li>Acute Lymphoblastic         <ul> <li>A: Is diagnosis relaps</li> <li>Other:</li> </ul> </li> <li>Additional Information:</li> </ol>	c Leukemia (ALL) sed or refractory CD22-positive E	B-cell precursor ALL? Yes No
Yes No 3. Has member experienced Yes No	nce of progressive disease while	e on inotuzumab ozogamicin therapy?  ated to inotuzumab ozogamicin therapy?
Additional Information:		
Prescriber Signature:  I certify that the indicated trea	ntment is medically necessary and	Date: d all information is true and correct to the
best of my knowledge.		ested if necessary. Failure to complete this

## PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

form in full will result in processing delays.

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

## **CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 88 5/3/2024